Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
13 Diciembre 2023 - 6:00AM
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage
biopharmaceutical company focused on transforming the lives of
patients and their families living with hyperphagia and severe
obesity caused by rare melanocortin-4 receptor (MC4R) pathway
diseases, is pleased to be a sponsor of the second annual
International Meeting on Pathway-Related Obesity: Vision &
Evidence (IMPROVE) that is being held in Paris, France from
December 13-15.
IMPROVE 2023 is a unique scientific meeting sponsored by Rhythm
for healthcare professionals based in Europe and around the world.
It is one of the few events globally that focuses solely on rare
MC4R pathway diseases. This year, approximately 150 healthcare
professionals will attend in person. Attendees are invited to
discuss and share the latest scientific developments and patient
care practices, including those driven by impairments in the MC4R
pathway, in which genetic deficiencies or injury can result in
hyperphagia (insatiable hunger) and early, rapid-onset severe
obesity.
“As we continue to learn more about MC4R pathway-related
diseases and the hyperphagia and severe obesity that present with
these diseases, collaborating with and learning from our colleagues
and leading experts will help us improve diagnosis and care for
patients and families,” said Karine Clément, M.D., Ph.D., Professor
of Nutrition at Pitié-Salpêtrière Hospital, Sorbonne Université and
Head of the INSERM Nutriomics Laboratory in Paris, who is serving
as Co-chair of IMPROVE 2023 with Hélène Dollfus, M.D., Ph.D.,
Hôpitaux Universitaires de Strasbourg, also in France. She added,
“We are excited to offer a full slate of academic presentations,
lectures and more than 50 poster presentations this year.”
About Rhythm Pharmaceuticals Rhythm is a
commercial-stage biopharmaceutical company committed to
transforming the lives of patients and their families living with
hyperphagia and severe obesity caused by rare melanocortin-4
receptor (MC4R) diseases. Rhythm’s headquarters is in Boston,
MA.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including without limitation statements regarding our
participation in upcoming events and presentations and the
potential positive impact of our IMPROVE conference for healthcare
professionals. Statements using words such as “expect”,
“anticipate”, “believe”, “may”, “will”, "aim" and similar terms are
also forward-looking statements. Such statements are subject to
numerous risks and uncertainties, including, but not limited to,
risks relating to our liquidity and expenses, our ability to enroll
patients in clinical trials, the design and outcome of clinical
trials, the ability to achieve necessary regulatory approvals,
risks associated with data analysis and reporting, failure to
identify and develop additional product candidates, unfavorable
pricing regulations, third-party reimbursement practices or
healthcare reform initiatives, risks associated with the laws and
regulations governing our international operations and the costs of
any related compliance programs, the impact of competition, risks
relating to product liability lawsuits, inability to maintain our
collaborations, or the failure of these collaborations, our
reliance on third parties, risks relating to intellectual property,
our ability to hire and retain necessary personnel, the impact of
the COVID-19 pandemic and general economic conditions on our
business and operations, including our preclinical studies,
clinical trials and commercialization prospects, failure to realize
the anticipated benefits of our acquisition of Xinvento B.V. or
significant integration difficulties related to the acquisition,
and the other important factors discussed under the caption “Risk
Factors” in our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023 and our other filings with the Securities and
Exchange Commission. Except as required by law, we undertake no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or
otherwise.
Corporate Contact: David
Connolly Executive Director, Investor Relations and Corporate
Communications Rhythm Pharmaceuticals,
Inc. 857-264-4280 dconnolly@rhythmtx.com
Media Contact: Adam Daley Berry &
Company Public Relations 212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Gráfica de Acción Histórica
De May 2023 a May 2024